CORGENTECH REPORTS DATA FROM TRIALS OF AVRINA

Corgentech has reported clinical data from two Phase I/II trials of Avrina, the company's NF-kappaB decoy drug candidate for the treatment of atopic dermatitis, a chronic skin disease also known as eczema that affects about 52 million adults and children in the U.S., Europe and Japan.

Exploratory analysis of efficacy was conducted in these trials to evaluate anti-inflammatory drug effect, and in both trials the lowest dose evaluated was the most efficacious. The dose of 0.25 percent, which was studied only in the U.S. trial, almost achieved statistical significance in the analysis of the combined eczema score despite the small patient population. The primary endpoint of these trials was to establish the safety and tolerability profile of Avrina.

Both trials enrolled patients with mild-to-moderate eczema and were multicenter studies that were randomized, double-blind and placebo-controlled. Periodic physician assessments of the targeted areas were made in both trials to measure the degree of symptom severity as well as patient evaluations of itchiness.